U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257120) titled 'KarXT Concentrations in the Breast Milk and Plasma of Lactating Females' on Nov. 21.
Brief Summary: The purpose of this study is to characterize the PK of xanomeline and trospium in breast milk and plasma in healthy lactating female participants, following multiple oral administration of KarXT in healthy lactating participants.
Study Start Date: April 14, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: Xanomeline/trospium chloride
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Karuna Therapeutics
Published by HT Digital Content Services with permission from...